Vyepti study misfire makes for learning experience for Lundbeck

Although it was on the smaller scale, a Vyepti study in China still did not produce the confidence-inspiring data Lundbeck had hoped for. ”We have learned a lot,” says CEO Deborah Dunsire.

Deborah Dunsire, CEO of Lundbeck | Photo: Gregers Tycho/ERH

Lundbeck met some resistance in the rollout of key product Vyepti, a preventive migraine treatment, when a smaller study in China did not deliver convincing results.

The Sunlight study, which could have smoothed over the way onto a niche market in China, did not meet its primary endpoint.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Further reading

Related articles

Latest news

See all jobs